Order Article Reprints

Chiorean EG, Damle SR, Zhen DB, Whittle M, George B, Hochster H, Coveler AL, Hendifar A, Dragovich T, Safyan RA, et al. Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001. Cancers. 2026; 18(3):507. https://doi.org/10.3390/cancers18030507

Chiorean, Elena Gabriela, Sheela R. Damle, David B. Zhen, Martin Whittle, Ben George, Howard Hochster, Andrew L. Coveler, Andrew Hendifar, Tomislav Dragovich, Rachael A. Safyan, and et al. 2026. "Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001" Cancers 18, no. 3: 507. https://doi.org/10.3390/cancers18030507

Chiorean, E. G., Damle, S. R., Zhen, D. B., Whittle, M., George, B., Hochster, H., Coveler, A. L., Hendifar, A., Dragovich, T., Safyan, R. A., King, G. T., Harris, W. P., Dion, B., Stoll D’Astice, A., Lee, A., Thorsen, S., Kugel, S., Rosenthal, A., & Hingorani, S. (2026). Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001. Cancers, 18(3), 507. https://doi.org/10.3390/cancers18030507